Reaction
Polymyositis reporting signals
As of the last recalculation, Polymyositis appears in 1,744 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is POSACONAZOLE DELAYED-RELEASE (PRR 37.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Posaconazole Delayed-Release | 34 | 37.7 | 37.8 |
| Posaconazole | 34 | 25.4 | 25.5 |
| Alemtuzumab | 37 | 23.3 | 23.3 |
| Gemfibrozil | 27 | 21.6 | 21.6 |
| Fludarabine Phosphate | 41 | 12.7 | 12.7 |
| Atorvastatin Calcium, Film Coated | 70 | 12.4 | 12.4 |
| Ciclesonide | 12 | 10.6 | 10.6 |
| Ursodiol | 18 | 10.0 | 10.0 |
| Ezetimibe | 54 | 8.8 | 8.8 |
| Ursosiol | 14 | 8.7 | 8.7 |
| Ipilimumab | 29 | 8.1 | 8.1 |
| Atorvastatin Calcium | 148 | 7.7 | 7.7 |
| Nivolumab | 60 | 7.6 | 7.6 |
| Thiotepa | 6 | 7.5 | 7.5 |
| Valacyclovir | 24 | 6.9 | 7.0 |
| Lapatinib | 8 | 6.2 | 6.2 |
| Pemetrexed | 11 | 6.2 | 6.2 |
| Busulfan | 8 | 6.1 | 6.1 |
| Ibrutinib | 37 | 5.6 | 5.6 |
| Nintedanib | 14 | 5.4 | 5.4 |
| Durvalumab | 8 | 4.7 | 4.7 |
| Inclisiran | 3 | 4.5 | 4.5 |
| Pembrolizumab | 38 | 4.4 | 4.4 |
| Atezolizumab | 12 | 3.7 | 3.7 |
| Encorafenib | 3 | 3.6 | 3.6 |